Pharmacological Treatment of Tachyarrhythmias in Acute Myocardial Infarction - a Review

1 B. Ibanez et al., “2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation,” Eur. Heart J., vol. 39, no. 2, pp. 119–177, 2018, doi: 10.1093/eurheartj/ehx393. IbanezB. “2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation,” Eur. Heart J. 39 2 119 177 10.1093/eurheartj/ehx393 Open DOISearch in Google Scholar

2 B. Gorenek et al., “Cardiac arrhythmias in acute coronary syndromes: Position paper from the joint EHRA, ACCA, and EAPCI task force,” Europace, 2014, doi: 10.1093/europace/euu208. GorenekB. “Cardiac arrhythmias in acute coronary syndromes: Position paper from the joint EHRA, ACCA, and EAPCI task force,” Europace 2014 10.1093/europace/euu208 Open DOISearch in Google Scholar

3 J. Schmitt, G. Duray, B. J. Gersh, and S. H. Hohnloser, “Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications,” European Heart Journal. 2009, doi: 10.1093/eurheartj/ehn579. SchmittJ. DurayG. GershB. J. HohnloserS. H. “Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications,” European Heart Journal 2009 10.1093/eurheartj/ehn579 Open DOISearch in Google Scholar

4 B. S. Crenshaw, S. R. Ward, C. B. Granger, A. L. Stebbins, E. J. Topol, and R. M. Califf, “Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience,” J. Am. Coll. Cardiol., vol. 30, no. 2, pp. 406–413, 1997, doi: 10.1016/S0735-1097(97)00194-0. CrenshawB. S. WardS. R. GrangerC. B. StebbinsA. L. TopolE. J. CaliffR. M. “Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience,” J. Am. Coll. Cardiol. 30 2 406 413 10.1016/S0735-1097(97)00194-0 Open DOISearch in Google Scholar

5 S. R. Lee, E. K. Choi, K. Han, M. J. Cha, and S. Oh, “Prevalence of non-valvular atrial fibrillation based on geographical distribution and socioeconomic status in the entire Korean population,” Korean Circ. J., vol. 48, no. 7, pp. 622–634, 2018, doi: 10.4070/kcj.2017.0362. LeeS. R. ChoiE. K. HanK. ChaM. J. OhS. “Prevalence of non-valvular atrial fibrillation based on geographical distribution and socioeconomic status in the entire Korean population,” Korean Circ. J. 48 7 622 634 10.4070/kcj.2017.0362 Open DOISearch in Google Scholar

6 tefania Matei et al., “The Relationship Between Psychosocial Status and Hypertensive Condition.,” Curr. Hypertens. Rep., vol. 20, no. 12, p. 102, Oct. 2018, doi: 10.1007/s11906-018-0902-y. Mateitefania “The Relationship Between Psychosocial Status and Hypertensive Condition.,” Curr. Hypertens. Rep. 20 12 102 Oct. 2018 10.1007/s11906-018-0902-y Open DOISearch in Google Scholar

7 E. G. Daoud et al., “Effect of an irregular ventricular rhythm on cardiac output,” Am. J. Cardiol., 1996, doi: 10.1016/S0002-9149(97)89297-1. DaoudE. G. “Effect of an irregular ventricular rhythm on cardiac output,” Am. J. Cardiol. 1996 10.1016/S0002-9149(97)89297-1 Open DOISearch in Google Scholar

8 J. P. Piccini and L. A. Allen, “Heart Failure Complicated by Atrial Fibrillation: Don’t Bury the Beta-Blockers Just Yet,” JACC: Heart Failure. 2017, doi: 10.1016/j.jchf.2016.12.003. PicciniJ. P. AllenL. A. “Heart Failure Complicated by Atrial Fibrillation: Don’t Bury the Beta-Blockers Just Yet,” JACC: Heart Failure 2017 10.1016/j.jchf.2016.12.003 Open DOISearch in Google Scholar

9 B. Gorenek and G. Kudaiberdieva, “Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features,” Curr. Cardiol. Rev., 2012, doi: 10.2174/157340312803760857. GorenekB. KudaiberdievaG. “Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features,” Curr. Cardiol. Rev. 2012 10.2174/157340312803760857 Open DOISearch in Google Scholar

10 Ş. Çelik, C. Erdöl, M. Baykan, Ş. Kaplan, and H. Kasap, “Relation between paroxysmal atrial fibrillation and left ventricular diastolic function in patients with acute myocardial infarction,” Am. J. Cardiol., 2001, doi: 10.1016/S0002-9149(01)01611-3. ÇelikŞ. ErdölC. BaykanM. KaplanŞ. KasapH. “Relation between paroxysmal atrial fibrillation and left ventricular diastolic function in patients with acute myocardial infarction,” Am. J. Cardiol. 2001 10.1016/S0002-9149(01)01611-3 Open DOISearch in Google Scholar

11 G. Hindricks et al., “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS),” Eur. Heart J., 2020, doi: 10.1093/eurheartj/ehaa612. HindricksG. “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS),” Eur. Heart J. 2020 10.1093/eurheartj/ehaa612 Open DOISearch in Google Scholar

12 Z. Kalarus et al., “Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: An European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and ,” Europace, 2019, doi: 10.1093/europace/euz163. KalarusZ. “Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: An European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and ,” Europace 2019 10.1093/europace/euz163 Open DOISearch in Google Scholar

13 C. T. January et al., “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation,” J. Am. Coll. Cardiol., 2019, doi: 10.1016/j.jacc.2019.01.011. JanuaryC. T. “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation,” J. Am. Coll. Cardiol. 2019 10.1016/j.jacc.2019.01.011 Open DOISearch in Google Scholar

14 J. B. Segal et al., “The evidence regarding the drugs used for ventricular rate control,” Journal of Family Practice. 2000. SegalJ. B. “The evidence regarding the drugs used for ventricular rate control,” Journal of Family Practice 2000 Search in Google Scholar

15 M. Metawee et al., “Digoxin and short term mortality after acute STEMI: Results from the MAGIC trial,” Int. J. Cardiol., 2016, doi: 10.1016/j.ijcard.2016.05.022. MetaweeM. “Digoxin and short term mortality after acute STEMI: Results from the MAGIC trial,” Int. J. Cardiol. 2016 10.1016/j.ijcard.2016.05.022 Open DOISearch in Google Scholar

16 S. P. Thomas et al., “Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial,” Am. Heart J., 2004, doi: 10.1016/s0002-8703(03)00526-x. ThomasS. P. “Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial,” Am. Heart J. 2004 10.1016/s0002-8703(03)00526-x Open DOISearch in Google Scholar

17 R. D. Lopes et al., “Digoxin and Mortality in Patients With Atrial Fibrillation,” J. Am. Coll. Cardiol., 2018, doi: 10.1016/j.jacc.2017.12.060. LopesR. D. “Digoxin and Mortality in Patients With Atrial Fibrillation,” J. Am. Coll. Cardiol. 2018 10.1016/j.jacc.2017.12.060 29519345 Open DOISearch in Google Scholar

18 J.-P. Collet et al., “2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation,” Eur. Heart J., pp. 1–79, 2020, doi: 10.1093/eurheartj/ehaa575. ColletJ.-P. “2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation,” Eur. Heart J. 1 79 2020 10.1093/eurheartj/ehaa575 32860058 Open DOISearch in Google Scholar

19 K. Saraf, P. Morris, P. Garg, P. Sheridan, and R. Storey, “Non-Vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations,” Postgrad. Med. J., vol. 90, no. 1067, pp. 520–528, 2014, doi: 10.1136/postgradmedj-2014-132605. SarafK. MorrisP. GargP. SheridanP. StoreyR. “Non-Vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations,” Postgrad. Med. J. 90 1067 520 528 10.1136/postgradmedj-2014-132605 25085900 Open DOISearch in Google Scholar

20 C. P. Cannon et al., “Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation,” N. Engl. J. Med., 2017, doi: 10.1056/nejmoa1708454. CannonC. P. “Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation,” N. Engl. J. Med. 2017 10.1056/nejmoa1708454 Open DOISearch in Google Scholar

21 C. M. Gibson et al., “Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI,” N. Engl. J. Med., 2016, doi: 10.1056/nejmoa1611594. GibsonC. M. “Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI,” N. Engl. J. Med. 2016 10.1056/nejmoa1611594 Open DOISearch in Google Scholar

22 R. D. Lopes et al., “Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation,” N. Engl. J. Med., 2019, doi: 10.1056/nejmoa1817083. LopesR. D. “Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation,” N. Engl. J. Med. 2019 10.1056/nejmoa1817083 Open DOISearch in Google Scholar

23 P. Vranckx et al., “Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial,” Eur. Heart J., 2020, doi: 10.1093/eurheartj/ehaa617. VranckxP. “Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial,” Eur. Heart J. 2020 10.1093/eurheartj/ehaa617 776763532860041 Open DOISearch in Google Scholar

24 F. J. Neumann et al., “2018 ESC/EACTS Guidelines on myocardial revascularization,” European Heart Journal. 2019, doi: 10.1093/eurheartj/ehy394. NeumannF. J. “2018 ESC/EACTS Guidelines on myocardial revascularization,” European Heart Journal 2019 10.1093/eurheartj/ehy394 30165437 Open DOISearch in Google Scholar

25 M. Eldar et al., “Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era,” Circulation, 1998, doi: 10.1161/01.CIR.97.10.965. EldarM. “Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era,” Circulation 1998 10.1161/01.CIR.97.10.965 Open DOISearch in Google Scholar

26 O. D. Pedersen, H. Bagger, L. Køber, and C. Torp-Pedersen, “The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution.,” Eur. Heart J., 1999, doi: 10.1053/euhj.1998.1352. PedersenO. D. BaggerH. KøberL. Torp-PedersenC. “The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution.,” Eur. Heart J. 1999 10.1053/euhj.1998.1352 10329066 Open DOISearch in Google Scholar

27 N. Danchin et al., “Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: Data from the FAST-MI register,” Heart, 2010, doi: 10.1136/hrt.2010.201574. DanchinN. “Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: Data from the FAST-MI register,” Heart 2010 10.1136/hrt.2010.201574 20965993 Open DOISearch in Google Scholar

28 R. D. Lopes et al., “Safety and Efficacy of Antithrombotic Strategies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials,” JAMA Cardiol., 2019, doi: 10.1001/jamacardio.2019.1880. LopesR. D. “Safety and Efficacy of Antithrombotic Strategies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials,” JAMA Cardiol. 2019 10.1001/jamacardio.2019.1880 658488531215979 Open DOISearch in Google Scholar

29 D. E. Thomas, N. Jex, and A. R. Thornley, “Ventricular arrhythmias in acute coronary syndromes-mechanisms and management,” Contin. Cardiol. Educ., vol. 3, no. 1, pp. 22–29, 2017, doi: 10.1002/cce2.51. ThomasD. E. JexN. ThornleyA. R. “Ventricular arrhythmias in acute coronary syndromes-mechanisms and management,” Contin. Cardiol. Educ. 3 1 22 29 10.1002/cce2.51 Open DOISearch in Google Scholar

30 J. P. Piccini et al., “Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction,” Crit. Care Med., vol. 39, no. 1, pp. 78–83, 2011, doi: 10.1097/CCM.0b013e3181fd6ad7. PicciniJ. P. “Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction,” Crit. Care Med. 39 1 78 83 10.1097/CCM.0b013e3181fd6ad7 301035220959785 Open DOISearch in Google Scholar

31 M. J. Janse and A. L. Wit, “Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction,” Physiological Reviews. 1989, doi: 10.1152/physrev.1989.69.4.1049. JanseM. J. WitA. L. “Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction,” Physiological Reviews 1989 10.1152/physrev.1989.69.4.1049 2678165 Open DOISearch in Google Scholar

32 M. Said et al., “Calcium-calmodulin dependent protein kinase II (CaMKII): A main signal responsible for early reperfusion arrhythmias,” J. Mol. Cell. Cardiol., 2011, doi: 10.1016/j.yjmcc.2011.08.010. SaidM. “Calcium-calmodulin dependent protein kinase II (CaMKII): A main signal responsible for early reperfusion arrhythmias,” J. Mol. Cell. Cardiol. 2011 10.1016/j.yjmcc.2011.08.010 Open DOISearch in Google Scholar

33 J. M. Di Diego and C. Antzelevitch, “Ischemic ventricular arrhythmias: Experimental models and their clinical relevance,” Hear. Rhythm, 2011, doi: 10.1016/j.hrthm.2011.06.036. Di DiegoJ. M. AntzelevitchC. “Ischemic ventricular arrhythmias: Experimental models and their clinical relevance,” Hear. Rhythm 2011 10.1016/j.hrthm.2011.06.036 Open DOISearch in Google Scholar

34 N. KH, T. T, Stebbins A, T. EJ, and Califf, “Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation nell’Infarto Miocardico (GISSI).,” Circulation, 1998. KHN. TT. StebbinsA EJT. Califf “Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation nell’Infarto Miocardico (GISSI).,” Circulation 1998 Search in Google Scholar

35 V. Barletta, I. Fabiani, C. Lorenzo, I. Nicastro, and V. Di Bello, “Sudden cardiac death: A review focused on cardiovascular imaging,” Journal of Cardiovascular Echography. 2014, doi: 10.4103/2211-4122.135611. BarlettaV. FabianiI. LorenzoC. NicastroI. Di BelloV. “Sudden cardiac death: A review focused on cardiovascular imaging,” Journal of Cardiovascular Echography 2014 10.4103/2211-4122.135611 Open DOISearch in Google Scholar

36 S. G. Priori et al., “2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea,” Eur. Heart J., vol. 36, no. 41, pp. 2793–2867l, 2015, doi: 10.1093/eurheartj/ehv316. PrioriS. G. “2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea,” Eur. Heart J. 36 41 2793 2867l 10.1093/eurheartj/ehv316 Open DOISearch in Google Scholar

37 C. J. Nalliah, S. Zaman, A. Narayan, J. Sullivan, and P. Kovoor, “Coronary artery reperfusion for ST elevation myocardial infarction is associated with shorter cycle length ventricular tachycardia and fewer spontaneous arrhythmias,” Europace, 2014, doi: 10.1093/europace/eut307. NalliahC. J. ZamanS. NarayanA. SullivanJ. KovoorP. “Coronary artery reperfusion for ST elevation myocardial infarction is associated with shorter cycle length ventricular tachycardia and fewer spontaneous arrhythmias,” Europace 2014 10.1093/europace/eut307 Open DOISearch in Google Scholar

38 A. Volpi, A. Cavalli, L. Santoro, and E. Negri, “Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction-results of the gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico (GISSI-2) database,” Am. J. Cardiol., 1998, doi: 10.1016/s0002-9149(98)00336-1. VolpiA. CavalliA. SantoroL. NegriE. “Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction-results of the gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico (GISSI-2) database,” Am. J. Cardiol. 1998 10.1016/s0002-9149(98)00336-1 Open DOISearch in Google Scholar

39 X. Z. He, S. H. Zhou, X. H. Wan, H. Y. Wang, Q. H. Zhong, and J. F. Xue, “The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome,” Clin. Cardiol., 2011, doi: 10.1002/clc.20818. HeX. Z. ZhouS. H. WanX. H. WangH. Y. ZhongQ. H. XueJ. F. “The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome,” Clin. Cardiol. 2011 10.1002/clc.20818 665254421259280 Open DOISearch in Google Scholar

40 R. Latini, A. P. Maggioni, M. Flather, P. Sleight, and G. Tognoni, “ACE inhibitor use in patients with myocardial infarction: Summary of evidence from clinical trials,” Circulation. 1995, doi: 10.1161/01.CIR.92.10.3132. LatiniR. MaggioniA. P. FlatherM. SleightP. TognoniG. “ACE inhibitor use in patients with myocardial infarction: Summary of evidence from clinical trials,” Circulation 1995 10.1161/01.CIR.92.10.3132 Open DOISearch in Google Scholar

41 J. S. Bundgaard et al., “Deep sedation as temporary bridge to definitive treatment of ventricular arrhythmia storm,” Eur. Hear. J. Acute Cardiovasc. Care, 2020, doi: 10.1177/2048872620903453. BundgaardJ. S. “Deep sedation as temporary bridge to definitive treatment of ventricular arrhythmia storm,” Eur. Hear. J. Acute Cardiovasc. Care 2020 10.1177/2048872620903453 32193944 Open DOISearch in Google Scholar

42 J. Bhar-Amato, W. Davies, and S. Agarwal, “Ventricular arrhythmia after acute myocardial infarction: ‘The perfect storm,’” Arrhythmia Electrophysiol. Rev., vol. 6, no. 3, pp. 134–139, 2017, doi: 10.15420/aer.2017.24.1. Bhar-AmatoJ. DaviesW. AgarwalS. “Ventricular arrhythmia after acute myocardial infarction: ‘The perfect storm,’” Arrhythmia Electrophysiol. Rev. 6 3 134 139 10.15420/aer.2017.24.1 561073129018522 Open DOISearch in Google Scholar

43 H. V. Huikuri, A. Castellanos, and R. J. Myerburg, “Sudden Death Due to Cardiac Arrhythmias,” N. Engl. J. Med., 2001, doi: 10.1056/nejmra000650. HuikuriH. V. CastellanosA. MyerburgR. J. “Sudden Death Due to Cardiac Arrhythmias,” N. Engl. J. Med. 2001 10.1056/nejmra000650 Open DOISearch in Google Scholar

44 J. P. Piccini et al., “Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Re,” Am. J. Cardiol., vol. 102, no. 11, pp. 1427–1432, 2008, doi: 10.1016/j.amjcard.2008.07.033. PicciniJ. P. “Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Re,” Am. J. Cardiol. 102 11 1427 1432 10.1016/j.amjcard.2008.07.033 Open DOISearch in Google Scholar

45 H. J. Dargie, “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial,” Lancet, 2001, doi: 10.1016/S0140-6736(00)04560-8. DargieH. J. “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial,” Lancet 2001 10.1016/S0140-6736(00)04560-8 Open DOISearch in Google Scholar

46 S. M. Al-Khatib et al., 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary, vol. 138, no. 13. 2018. Al-KhatibS. M. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary 138 13 2018 10.1161/CIR.000000000000061530354427 Search in Google Scholar

47 F. Mehraein, “A Review on Amiodarone as an Antiarrhythmic Drug,” Abnorm. Hear. Rhythm., 2015, doi: 10.5772/60418. MehraeinF. “A Review on Amiodarone as an Antiarrhythmic Drug,” Abnorm. Hear. Rhythm. 2015 10.5772/60418 Open DOISearch in Google Scholar

48 R. M. L. Colunga Biancatelli, V. Congedo, L. Calvosa, M. Ciacciarelli, A. Polidoro, and L. Iuliano, “Adverse reactions of amiodarone,” J. Geriatr. Cardiol., vol. 16, no. 7, pp. 552–566, 2019, doi: 10.11909/j.issn.1671-5411.2019.07.004. Colunga BiancatelliR. M. L. CongedoV. CalvosaL. CiacciarelliM. PolidoroA. IulianoL. “Adverse reactions of amiodarone,” J. Geriatr. Cardiol. 16 7 552 566 10.11909/j.issn.1671-5411.2019.07.004 668951631447894 Open DOISearch in Google Scholar